Clinical Trial Update: A Study of SHR6508 in Secondary Hyperparathyroidism [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHR6508 in secondary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• SHR6508 (SHR6508)

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: UNKNOWN